Austrian immuno-oncology firm Apeiron Biologics today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), and has the potential to block the infection of cells by the novel SARS-CoV-2 virus (COVID-19), and reduce lung injury. The Pharma Letter
Sunday, April 5, 2020
Apeiron Biologics moves forward with APN01 for treatment of COVID-19
Austrian immuno-oncology firm Apeiron Biologics today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), and has the potential to block the infection of cells by the novel SARS-CoV-2 virus (COVID-19), and reduce lung injury. The Pharma Letter
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment